Contact Us



Antibody to Polyethylene glycol (PEG)

It is increasingly common practice to enhance the efficacy of drugs or therapeutic agents through PEGylation. The attachment of PEG to a drug or therapeutic protein increases the in vivo half life of the agent by altering the surface of the molecule. The result is improved drug solubility, increased stability, and a drug rendered non-immunogenic; ultimately giving it the desired extended circulating life. With such innovation comes the need for new tools to validate, track and improve upon the process. Maine Biotechnology Services has developed an antibody that recognizes all forms of PEG; large, small and branched. There are broad applications for this antibody in both production and R&D settings. For production purposes, our PEG antibody can be a vital tool for propelling therapeutics to market by serving as a positive control anti-drug antibody, measuring clearance of a drug, or simply in a western blot as a QA release confirming PEGylation. Our antibody serves well as a tool aiding the refinement of the PEGylation process and purification of the resulting proteins by recognizing all forms of PEG

Benefits

Technology

Our antibody was developed in a CD rat immunized with 5 kDa PEG conjugated to KLH using the MBS rapid immunization protocol. The fusion resulted in several IgM clones specific for PEG. The strongest clone, as determined by cell culture quality and specific antibody signal to PEG, was selected for subcloning, production and purification. The monoclonal antibody is produced in vitro and purified using a proprietary multi-platform protocol. By indirect ELISA the antibody recognizes linear 20 kDa PEG, linear 5 kDa PEG, linear 600 Da PEG and 10 kDa branched PEG. It also binds to BSA conjugated PEG by western blot.

ELISA Data

Comparison of Rat anti-PEG IgM MAb (2.5ug/ml) in Indirect ELISA against various sized linear
and branched PEG conjugates as well as linear PEG unconjugated (all antigens at 2ug/ml).

Western Blot Data